New aspects of natural products in drug discovery.

During the past 15 years, most large pharmaceutical companies have decreased the screening of natural products for drug discovery in favor of synthetic compound libraries. Main reasons for this include the incompatibility of natural product libraries with high-throughput screening and the marginal improvement in core technologies for natural product screening in the late 1980s and early 1990 s. Recently, the development of new technologies has revolutionized the screening of natural products. Applying these technologies compensates for the inherent limitations of natural products and offers a unique opportunity to re-establish natural products as a major source for drug discovery. Examples of these new advances and technologies are described in this review.

[1]  M. Goodfellow,et al.  Amycolatopsis plumensis sp. nov., a novel bioactive actinomycete isolated from a New-Caledonian brown hypermagnesian ultramafic soil. , 2005, International journal of systematic and evolutionary microbiology.

[2]  Ben Shen,et al.  Microbial genomics for the improvement of natural product discovery. , 2006, Current opinion in microbiology.

[3]  M. Kurz,et al.  Antibiotics GE23077, novel inhibitors of bacterial RNA polymerase. I. Taxonomy, isolation and characterization. , 2004, The Journal of antibiotics.

[4]  M. O'Neil-Johnson,et al.  High-throughput method for the production and analysis of large natural product libraries for drug discovery. , 2002, Analytical chemistry.

[5]  E. Cundliffe.  Antibiotic production by actinomycetes: the Janus faces of regulation , 2006, Journal of Industrial Microbiology and Biotechnology.

[6]  Jürgen Bajorath.  Chemoinformatics methods for systematic comparison of molecules from natural and synthetic sources and design of hybrid libraries , 2002, J. Comput. Aided Mol. Des..

[7]  Ming Xian,et al.  Toward understanding how the lactone moiety of discodermolide affects activity. , 2005, Journal of the American Chemical Society.

[8]  Gerard D. Wright,et al.  Biosynthesis of sulfated glycopeptide antibiotics by using the sulfotransferase StaL. , 2006, Chemistry & biology.

[9]  Emmanuel Zazopoulos,et al.  Improving Drug Discovery From Microorganisms , 2005 .

[10]  János Bérdy,et al.  Bioactive microbial metabolites. , 2005, The Journal of antibiotics.

[11]  D. Payne,et al.  Selection of Retapamulin, a Novel Pleuromutilin for Topical Use , 2006, Antimicrobial Agents and Chemotherapy.

[12]  K. S. Lam,et al.  Drug discovery from natural products , 2006, Journal of Industrial Microbiology and Biotechnology.

[13]  R. Müller,et al.  Establishment of a real-time PCR protocol for expression studies of secondary metabolite biosynthetic gene clusters in the G/C-rich myxobacterium Sorangium cellulosum So ce56. , 2006, Journal of biotechnology.

[14]  S. Donadio,et al.  Antibiotic-producing ability by representatives of a newly discovered lineage of actinomycetes. , 2006, Microbiology.

[15]  S. Ōmura,et al.  Isolation and Identification of Three New 5-Alkenyl-3,3(2H)-furanones from Two Streptomyces species using a Genomic Screening Approach , 2006, The Journal of Antibiotics.

[16]  H. Kwon,et al.  Marinomycins A-D, antitumor-antibiotics of a new structure class from a marine actinomycete of the recently discovered genus "marinispora". , 2006, Journal of the American Chemical Society.

[17]  Gurmeet Kaur,et al.  Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin , 2004, Clinical Cancer Research.

[18]  K. S. Lam,et al.  Synthesis and antibacterial activity of nocathiacin I analogues. , 2006, Bioorganic & medicinal chemistry letters.

[19]  Chunlei Zhang,et al.  Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.

[20]  S. Steinberg,et al.  Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer , 2006, Investigational New Drugs.

[21]  A Ganesan,et al.  Natural products as a hunting ground for combinatorial chemistry. , 2004, Current opinion in biotechnology.

[22]  T. Meyer,et al.  Function oriented synthesis: the design, synthesis, PKC binding and translocation activity of a new bryostatin analog. , 2004, Current drug discovery technologies.

[23]  Ronald N. Jones,et al.  Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004). , 2006, The Journal of antimicrobial chemotherapy.

[24]  G. Strobel.  Harnessing endophytes for industrial microbiology. , 2006, Current opinion in microbiology.

[25]  Jacques Vervoort,et al.  Hyphenated chromatographic techniques for the rapid screening and identification of antioxidants in methanolic extracts of pharmaceutically used plants. , 2006, Journal of chromatography. A.

[26]  Andrew G Myers,et al.  A Convergent Enantioselective Route to Structurally Diverse 6-Deoxytetracycline Antibiotics , 2005, Science.

[27]  Paul R Jensen,et al.  Developing a new resource for drug discovery: marine actinomycete bacteria , 2006, Nature chemical biology.

[28]  Mark S Butler,et al.  Natural products--the future scaffolds for novel antibiotics? , 2006, Biochemical pharmacology.

[29]  C. Farnet,et al.  Genomic Analyses Lead to Novel Secondary Metabolites , 2006, The Journal of Antibiotics.

[30]  Sylvie Lautru,et al.  Discovery of a new peptide natural product by Streptomyces coelicolor genome mining , 2005, Nature chemical biology.

[31]  Brian O. Bachmann,et al.  A genomics-guided approach for discovering and expressing cryptic metabolic pathways , 2003, Nature Biotechnology.

[32]  Emmanuel Zazopoulos,et al.  Microbial genomics as a guide to drug discovery and structural elucidation: ECO-02301, a novel antifungal agent, as an example. , 2005, Journal of natural products.

[33]  T. Mansour,et al.  Muraymycins, novel peptidoglycan biosynthesis inhibitors: synthesis and SAR of their analogues. , 2003, Bioorganic & medicinal chemistry letters.

[34]  Michael Müller,et al.  Chemical diversity through biotransformations. , 2004, Current opinion in biotechnology.

[35]  Hai-yin He.  Mannopeptimycins, a novel class of glycopeptide antibiotics active against gram-positive bacteria , 2005, Applied Microbiology and Biotechnology.

[36]  K. S. Lam,et al.  Discovery of novel metabolites from marine actinomycetes. , 2006, Current opinion in microbiology.

[37]  J. Vervoort,et al.  Identification of the major constituents of Hypericum perforatum by LC/SPE/NMR and/or LC/MS. , 2007, Phytochemistry.

[38]  Nagamani Bora,et al.  Diversity and biogeography of marine actinobacteria. , 2006, Current opinion in microbiology.

[39]  G. Stein,et al.  Tigecycline: a critical analysis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  Lynda Tremblay,et al.  Macrocyclic ketone analogues of halichondrin B. , 2004, Bioorganic & medicinal chemistry letters.

[41]  Y. Hayashi,et al.  NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent , 2006, Anti-cancer drugs.

[42]  Heinz G Floss,et al.  Combinatorial biosynthesis--potential and problems. , 2006, Journal of biotechnology.

[43]  J. Bennett,et al.  Fungal secondary metabolism — from biochemistry to genomics , 2005, Nature Reviews Microbiology.

[44]  Herbert Waldmann,et al.  Design of compound libraries based on natural product scaffolds and protein structure similarity clustering (PSSC). , 2005, Molecular bioSystems.

[45]  A. Demain,et al.  Natural products : drug discovery and therapeutic medicine , 2005 .

[46]  W. Stadler,et al.  A phase II study of depsipeptide in refractory metastatic renal cell cancer. , 2006, Clinical genitourinary cancer.

[47]  P. Kulanthaivel,et al.  Novel Lipoglycopeptides as Inhibitors of Bacterial Signal Peptidase I* , 2004, Journal of Biological Chemistry.

[48]  C. Gualerzi,et al.  Specific, efficient, and selective inhibition of prokaryotic translation initiation by a novel peptide antibiotic. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Peter H. Janssen,et al.  Effects of Growth Medium, Inoculum Size, and Incubation Time on Culturability and Isolation of Soil Bacteria , 2005, Applied and Environmental Microbiology.

[50]  P. Beale,et al.  Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG) , 2006, Cancer Chemotherapy and Pharmacology.

[51]  D. Chauhan,et al.  A novel proteasome inhibitor NPI-0052 as an anticancer therapy , 2006, British Journal of Cancer.

[52]  David J Newman,et al.  Natural products as sources of new drugs over the period 1981-2002. , 2003, Journal of natural products.

[53]  Klaus Albert,et al.  LC–NMR coupling technology: recent advancements and applications in natural products analysis , 2005, Magnetic resonance in chemistry : MRC.

[54]  F. Koehn,et al.  The evolving role of natural products in drug discovery , 2005, Nature Reviews Drug Discovery.

[55]  W. Kiefer,et al.  Novel insights and therapeutical applications in the field of inhibitors of COX-2. , 2004, Current Medicinal Chemistry.

[56]  F. Bambeke.  Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. , 2006 .

[57]  P. Wright,et al.  The current status of natural products from marine fungi and their potential as anti-infective agents , 2006, Journal of Industrial Microbiology and Biotechnology.

[58]  M. Bibb,et al.  Regulation of secondary metabolism in streptomycetes. , 2005, Current opinion in microbiology.

[59]  J. Rohr,et al.  Combinatorial biosynthesis of antitumor indolocarbazole compounds. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Jun Wang,et al.  Platensimycin is a selective FabF inhibitor with potent antibiotic properties , 2006, Nature.

[61]  G. Schneider,et al.  Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries. , 2001, Journal of combinatorial chemistry.

[62]  R. Wenzel,et al.  Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent , 2006, Expert review of anti-infective therapy.

[63]  George G Harrigan,et al.  Chemical and biological integrity in natural products screening. , 2005, Combinatorial chemistry & high throughput screening.

[64]  J. Thorson,et al.  Diversifying vancomycin via chemoenzymatic strategies. , 2005, Organic letters.

[65]  J. Portugal.  Chartreusin, elsamicin A and related anti-cancer antibiotics. , 2003, Current medicinal chemistry. Anti-cancer agents.

[66]  Alan P. Johnson.  Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. , 2007, Current opinion in investigational drugs.

[67]  A. Bull,et al.  Diversity of actinomycetes isolated from Challenger Deep sediment (10,898 m) from the Mariana Trench , 2006, Extremophiles.

[68]  Miklos Feher,et al.  Property Distributions: Differences between Drugs, Natural Products, and Molecules from Combinatorial Chemistry , 2003, J. Chem. Inf. Comput. Sci..

[69]  eun-joo kim,et al.  General pharmacology of CKD-732, a new anticancer agent: effects on central nervous, cardiovascular, and respiratory system. , 2005, Biological & pharmaceutical bulletin.

[70]  Philipp Krastel,et al.  Recent developments in antibacterial drug discovery: microbe-derived natural products – from collection to the clinic , 2006, Expert opinion on investigational drugs.

[71]  T. Mincer,et al.  Culturable marine actinomycete diversity from tropical Pacific Ocean sediments. , 2005, Environmental microbiology.

[72]  R. Müller,et al.  Analysis of myxobacterial secondary metabolism goes molecular , 2006, Journal of Industrial Microbiology and Biotechnology.

[73]  Christopher T. Walsh,et al.  Lessons from natural molecules , 2004, Nature.

[74]  Mohamed A. Marahiel,et al.  Chemoenzymatic and Template-Directed Synthesis of Bioactive Macrocyclic Peptides , 2006, Microbiology and Molecular Biology Reviews.

[75]  Mark S Butler,et al.  The role of natural product chemistry in drug discovery. , 2004, Journal of natural products.

[76]  M. Butler.  Natural products to drugs: natural product-derived compounds in clinical trials. , 2005, Natural product reports.

[77]  A Ganesan,et al.  Natural products and combinatorial chemistry: back to the future. , 2004, Current opinion in chemical biology.

[78]  C. Ireland,et al.  Marine-derived fungi: a chemically and biologically diverse group of microorganisms. , 2004, Natural product reports.

[79]  Ian Paterson,et al.  The Renaissance of Natural Products as Drug Candidates , 2005, Science.

[80]  Axel Zeeck,et al.  Big Effects from Small Changes: Possible Ways to Explore Nature's Chemical Diversity , 2002, Chembiochem : a European journal of chemical biology.

[81]  G. Pond,et al.  A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas , 2006, British Journal of Cancer.

[82]  M. Goodfellow,et al.  Exploration of Amycolatopsis diversity in soil using genus-specific primers and novel selective media. , 2006, Systematic and applied microbiology.